The PRMT1 inhibitor MS023 effectively inhibits METTL14 methylation and markedly reduces its capacity to promote cancer cell proliferation and clonogenicity, suggesting that PRMT1 is pivotal in carcinogenesis through the regulation of METTL14's PTM [66]. Here, METTL14 is linked to cancer.